Renal Cell Carcinoma

At a live, virtual Case-Based Roundtable meeting, Bradley McGregor, MD, discussed with fellow physicians how best to integrate new approaches to treatment for patients with relapsed or refractory clear cell renal cell carcinoma.

In the fifth article of this series, Hans Hammers, MD, PhD, outlines established treatment paradigms and discusses clinical trial data and ongoing research that are informing the future treatment landscape of advanced renal cell carcinoma.

During a Targeted Oncology™ Community Case Forum™ event, Hans Hammers, MD, discussed trials that shed light on the role of adjuvant therapies for patients with stage II and III renal cell carcinoma.

Samer A. Srour, MD, discusses the results of the phase 1 TRAVERSE trial of ALLO-316 in patients with advanced renal cell carcinoma.

Eric Singer, MD, discusses the relevant data that led to the approval of sunitinib in the adjuvant treatment setting for renal cell carcinoma.

In part 1 of a 2-part series, Hans Hammers, MD, PhD, discusses the current landscape for treating patients with advanced renal cell carcinoma who have had 1 or 2 prior therapies and how tivozanib fits into current treatment practices.

During a Targeted Oncology™ Case-Based Roundtable™ event, Elizabeth M. Wulff-Burchfield, MD, and participants discussed the choice of frontline options for a patient with favorable-risk clear cell renal cell carcinoma, and how liver or lung metastases affect the decision.

VEGFR inhibitors, mTOR inhibitors, and immune checkpoint inhibitors have been studied as adjuvant therapy for patients with RCC. However, conflicting data from phase 3 trials have left investigators unclear on what their role is.

Combining sintilimab and axitinib led to tumor shrinkage and a tolerable safety profile in patients with advanced FH-deficient renal cell carcinoma.

During a Targeted Oncology™ Case-Based Roundtable™ event, Sumanta Kumar Pal, MD, and participants discussed next-line therapy for a patient with advanced clear cell renal cell carcinoma who progressed on axitinib/pembrolizumab and single-agent cabozantinib.

During a Targeted Oncology™ Case-Based Roundtable™ event, Manojkumar Bupathi, MD, MS, discussed with participants how risk groups affect their choice of first-line treatment in renal cell carcinoma. This is the first of 2 articles based on this event.

In an interview with Targeted Oncology, Alexander Helfand, MD discussed the current standard practice for testing patients with renal cell carcinoma and administering immunotherapy or targeted therapy.

Expert genitourinary oncologists close their discussion with advice to community oncologists treating renal cell carcinoma.

Data from the phase 3 KEYNOTE-426 continue to support pembrolizumab plus axitinib as a standard of care for patients with clear cell renal cell carcinoma.

Thomas Hutson, DO, PharmD, FACP has updated reported efficacy results from the phase 2 CLEAR study.

The immunotherapy and tyrosine kinase inhibitor combination cabozantinib plus nivolumab and piplimumab induces response in nearly half of patients treated.

Positive results have been reported from phase 1/2 KEYMAKER-U03B study, and belzutifan plus lenvatinib is being further investigated in the phase 3 LITESPARK-011 study (NCT04586231).

A panel of experts on renal cell carcinoma discuss triplet therapy and review COSMIC-313, a study of cabozantinib, nivolumab, and ipilimumab in the first line.

Expert oncologists discuss the management of immune-related adverse events in renal cell carcinoma.

An overview of adverse event and toxicity considerations with TKI therapies in renal cell carcinoma.

Expert oncologists review data updates on IO-IO regimens in the treatment of advanced RCC, including CheckMate 214, and discuss treatment selection among IO-IO and IO-TKI combinations.

While cabozantinib, nivolumab, and ipilimumab resulted in a longer progression-free survival among patients with renal cell carcinoma vs nivolumab and ipilimumab alone, more adverse events were observed with the combination.

During a Targeted Oncology™ Case-Based Roundtable™ event, Hans Hammers, MD, PhD, and participants discussed their experiences using lenvatinib to treat patients with advanced clear cell renal cell carcinoma.

Multidisciplinary experts discuss the role of concurrent radiation in the treatment of renal cell carcinoma.

A panel of experts in renal cell carcinoma present the case of a 59-year-old woman with renal cell carcinoma and discuss systemic therapy options.

In an interview with Targeted Oncology, Samer A. Srour, MD, discussed the results from the phase 3 TRAVERSE study and the potential role of chimeric antigen receptor T-cell therapy in renal cell carcinoma.

Hans Hammers, MD, PhD, discusses the evolving treatment paradigms in patients with advanced renal cell carcinoma and how recent clinical trial data may optimize future treatment selections.

During a Targeted Oncology™ Case-Based Roundtable™ event, Benjamin Garmezy, MD, reviewed updated results of trial of frontline combination therapies for patients with advanced renal cell carcinoma.

RCC experts discuss second-line therapy options following progression on first-line IO-TKI regimen.

Detailed insights on how the choice of tyrosine kinase inhibitors (TKIs) in IO-TKI regimens impact the treatment of advanced renal cell carcinoma.